Relationship Between Intraocular Pressure and the True Rate of Functional and Structural Progression in the United Kingdom Glaucoma Treatment Study.
Montesano Giovanni, Rabiolo Alessandro, Ometto Giovanni, Crabb David P, Garway-Heath David F
AI Summary
This study found visual field progression appeared faster than structural, but a floor effect explained this; IOP similarly accelerated both, emphasizing comprehensive monitoring.
Abstract
Purpose
To investigate the effect of average intraocular pressure (IOP) on the true rate of glaucoma progression (RoP) in the United Kingdom Glaucoma Treatment Study (UKGTS).
Methods
UKGTS participants were randomized to placebo or Latanoprost drops and monitored for up to two years with visual field tests (VF, 24-2 SITA standard), IOP measurements, and optic nerve imaging. We included eyes with at least three structural or functional assessments (VF with <15% false-positive errors). Structural tests measured rim area (RA) with Heidelberg retina tomography (HRT) and average peripapillary retinal nerve fiber layer (pRNFL) thickness with optical coherence tomography (OCT). One eye of 436 patients (222 on Latanoprost) was analyzed. A Bayesian hierarchical model estimated the true RoP of VF and structural metrics, and their correlations, using sign-reversed multivariable exponential distribution. RA and pRNFL measurements were converted to a dB scale, matching the VF metric (mean deviation [MD]). The effect of average IOP on the true RoPs was estimated.
Results
True RoP at the mean average IOP (17 mm Hg) was faster (P < 0.001) for VF-MD (-0.59 [-0.73, -0.48] dB/year) than HRT-RA (-0.05 [-0.07, -0.03] dB/year) and OCT-pRNFL (-0.08 [-0.11, -0.06] dB/year). The proportional acceleration of RoP per mm Hg increase was, however, not significantly different (smallest P = 0.15). Accounting for the structural floor-effect largely eliminated the differences in RoPs (smallest P = 0.25).
Conclusions
VF appeared to deteriorate at a faster rate than structural measurements. However, this could be explained by the floor-effect from nonfunctional tissue. IOP induced a similar acceleration in RoP per mm Hg increase.
MeSH Terms
Shields Classification
Key Concepts5
In the United Kingdom Glaucoma Treatment Study (UKGTS), the true rate of progression (RoP) for visual field mean deviation (VF-MD) at a mean average intraocular pressure (IOP) of 17 mm Hg was -0.59 dB/year (95% CI: -0.73, -0.48), which was faster (P < 0.001) than for HRT-RA and OCT-pRNFL.
In the United Kingdom Glaucoma Treatment Study (UKGTS), the true rate of progression (RoP) for HRT-RA at a mean average intraocular pressure (IOP) of 17 mm Hg was -0.05 dB/year (95% CI: -0.07, -0.03), which was slower (P < 0.001) than for VF-MD.
In the United Kingdom Glaucoma Treatment Study (UKGTS), the true rate of progression (RoP) for OCT-pRNFL at a mean average intraocular pressure (IOP) of 17 mm Hg was -0.08 dB/year (95% CI: -0.11, -0.06), which was slower (P < 0.001) than for VF-MD.
In the United Kingdom Glaucoma Treatment Study (UKGTS), the proportional acceleration of the true rate of glaucoma progression (RoP) per mm Hg increase in average intraocular pressure (IOP) was not significantly different across visual field and structural metrics (smallest P = 0.15).
In the United Kingdom Glaucoma Treatment Study (UKGTS), the apparent faster deterioration of visual field measurements compared to structural measurements could be explained by accounting for the structural floor-effect, which largely eliminated the differences in rates of progression (smallest P = 0.25).
Related Articles5
The Glaucoma Intensive Treatment Study (GITS): A Randomized Controlled Trial Comparing Intensive and Standard Treatment on 5 Years Visual Field Development.
Randomized Controlled TrialDoes the Visual Field Improve After Initiation of Intraocular Pressure Lowering in the United Kingdom Glaucoma Treatment Study?
Randomized Controlled TrialThe effect of long-term intraocular pressure reduction on the differential light sensitivity in glaucoma suspects.
Cohort StudyOphthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502.
Case SeriesComparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.